Ibrutinib, a Bruton tyrosine kinase (BTK) inhibitor, has become a standard in the treatment of chronic lymphocytic leukemia (CLL) patients [1,2]. This evidence concerns the gene BTK and B-cell chronic lymphocytic leukemia.